Atlas Trials

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Clinical trial NCT05390840 · UNKNOWN

Trial details

NCT number
NCT05390840
Sponsor
Theratocular Biotek Co.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Age-Related Macular Degeneration
Start date
2022-08-09
Primary completion
2024-03-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.